ERBB2 and congestive heart failure: The Cardiac Review and Evaluation Committee (CREC), a retrospective study aiming at the evaluation of the cardiotoxicity of the anti-HER2 agent trastuzumab with or without concomitant anthracycline treatment, defined cardiotoxicity as a reduction in LVEF of at least 5% to below 55% with concomitant signs or symptoms of congestive heart failure (CHF), or a decrease in LVEF of at least 10% to below 55% without associated signs or symptoms (8).